ZFP36L2 and psoriasis: Plotting ZIST program member expression against ZFP36L2 levels in Trms/Th17/Tc17 cells from these pre- and mid-treatment psoriasis lesions shows that despite resolution of visible inflammatory plaques, the overall inflammatory-suppressive gradient in T cells remains sharply suppressed (Figure 6C).